Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +336.94%
#4 aPriori aPriori +113.84%
#5 Bedrock Bedrock +73.65%
#6 Cysic Cysic +47.27%
#7 Prom Prom +39.78%
#8 Playnance Playnance +35.16%
#9 COTI COTI +30.31%
#10 Nillion Nillion +22.86%
Coin of the day
Wrapped One Wrapped One
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Arch Therapeutics, Inc. Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

ARTH
Rang in Aktien #42478
Arch Therapeutics, Inc., operating alongside its affiliated companies,... Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Aktienkurs
$0.0009
Zuletzt synchronisiert: 2025-05-27
Marktkapitalisierung
$1.15K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Arch Therapeutics, Inc. (ARTH)

Kategorie

Healthcare
Gewinn für Arch Therapeutics, Inc. (ARTH)
Gewinn im Jun 2024 TTM: $-12.26M
Laut den aktuellen Finanzberichten von Arch Therapeutics, Inc. betragen die aktuellen Gewinne des Unternehmens $-12.26M. Im Jahr 2022 erzielte das Unternehmen einen Gewinn von $-5.28M, eine Steigerung gegenüber dem Gewinn im Jahr 2021, der $-6.24M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Arch Therapeutics, Inc. von 2011 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-12.26M 75.61%
2023 $-6.98M 32.35%
2022 $-5.28M -15.46%
2021 $-6.24M 33.02%
2020 $-4.69M 3.16%
2019 $-4.55M -5.53%
2018 $-4.81M -38.19%
2017 $-7.79M 29.98%
2016 $-5.99M 103.30%
2015 $-2.95M -63.80%
2014 $-8.14M 339.25%
2013 $-1.85M 4,963.48%
2012 $-36.61K 626.84%
2011 $-5.04K 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -43,115.92%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -16,007.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -24,611.12%
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR